more_reports

Ed Arce

H.C. Wainwright & Co.

Image: Ed Arce

Ed Arce is a managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright & Co. Previously, Arce was a senior research analyst with ROTH Capital Partners. Prior to ROTH, he covered biotechnology, biopharmaceutical, specialty pharmaceutical and select medical device companies as an analyst at MLV & Co. Prior to MLV, Arce covered the biotechnology sector at Wedbush Securities, and large-cap pharmaceuticals at UBS Securities. Arce started his equity research career in 2005 as a research associate at First Albany Capital, covering specialty and generic pharmaceutical companies.
He holds a master of science degree in finance (MSF) degree from Boston College, as well as a master's degree in business administration and a bachelor's degree in civil engineering, both from Florida International University. Mr. Arce is a board-licensed professional engineer, and a Level III CFA candidate.

Recent Articles

Biotech Secures Additional Funding, Extending Cash Runway 12/27/2023

Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co.

US Biotech's Anti-Fungal Wins European Approvals 12/22/2023

Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co.

Key Catalyst for US Biopharma Stock on Track for Q4/23 06/09/2023

Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report.


Recent Quotes

"DRRX's Phase 2b DUR-928 AH trial is set to begin in mid-2020."

— Ed Arce, H.C. Wainwright & Co. (3/4/20)
more >



Due to permission requirements, not all quotes are shown.